论文部分内容阅读
目的观察马来酸曲美布汀联合培菲康治疗肠易激综合征(IBS)的临床疗效及安全性。方法以ROMAⅢ为标准选取IBS患者150例,随机分为观察组76例和对照组74例。两组均停用其他治疗IBS的药物,禁用影响胃肠功能的药物,均给予马来酸曲美布汀,200mg/次,3次/d,观察组在此基础上同时加服药物培菲康,2片/次,3次/d,观察组和治疗组均以4周为一个疗程。观察治疗后IBS症状变化及药物不良反应。结果观察组在治疗4周后症状好转明显高于对照组,总有效率明显高于对照组,差异有统计学意义(P<0.01);两组不良反应发生率无显著差异。结论马来酸曲美布汀联合培菲康治疗IBS效果显著,安全性高。
Objective To observe the clinical efficacy and safety of trimebutine maleate combined with Peifei Kang in the treatment of irritable bowel syndrome (IBS). Methods 150 IBS patients were selected according to ROMA Ⅲ standard, and randomly divided into observation group (76 cases) and control group (74 cases). Two groups were discontinued other drugs for the treatment of IBS, disable the drugs that affect the gastrointestinal function, are given trimebutine maleate, 200mg / time, 3 times / d, the observation group on the basis of this at the same time add the drug Pei Fei Kang, 2 tablets / time, 3 times / d, observation group and treatment group were 4 weeks for a course of treatment. Observed after treatment of IBS symptoms and adverse drug reactions. Results The improvement of symptoms in the observation group after 4 weeks of treatment was significantly higher than that of the control group, and the total effective rate was significantly higher than that of the control group (P <0.01). There was no significant difference in adverse reactions between the two groups. Conclusion Trimebutine maleate combined with Peifei Kang treatment of IBS significant effect, high safety.